Hypertension with asymptomatic hyperuricemia
Conditions
Interventions
Experimental group:Take sacubitril/valsartan with an initial treatment dose of 200 mg once a day.
Control group:Taking valsartan: 160mg, once a day
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years; 2.Patients with mild to moderate essential hypertension (with or without medication), sitting systolic blood pressure (SBP) >=140mmHg and = 90mmHg and = 420 umol/L.
Exclusion criteria
Exclusion criteria: 1.A history of gout and kidney stones within two years; 2.Patients taking anti uric acid drugs; 3.Heart failure within 3 months; History of cerebrovascular accident, transient ischemic attack, unstable angina pectoris, myocardial infarction and clinically significant arrhythmia; 4.Severe liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis, or the level of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 2.0 times of the upper limit of normal (ULN), or the total bilirubin exceeds 1.5 times of ULN; 5.The estimated glomerular filtration rate (EGFR) was less than 60 ml / min / 1.73 m^2 for severe renal injury; 6.Alcohol or drug abuse, cachexia and mental disorders; 7.Known to be allergic or intolerant to sacubitril/valsartan and valsartan; 8.Patients have family planning and can't use contraception or lactation; 9.Have participated in or are participating in other clinical trials 4 weeks before screening; 10.Subjects considered unsuitable for further study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uric acid change value;Blood pressure, heart rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical criterion; | — |
Countries
China
Contacts
Public ContactDong Yifei
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed